Huberman Lab
Dr. Peter Attia: Supplements for Longevity & Their Efficacy
Dr. Peter Attia
I mean, I think part of the reason why I think there's much better research going on with rapamycin is that there's really no commercial interest in rapamycin. Like nobody's going to make money selling rapamycin. Because it's so cheap? Well, yeah. And it's actually not cheap, but it's a drug that is off-patent. So this is a drug that was approved by the FDA 25 years ago.
0
💬
0
Comments
Log in to comment.
There are no comments yet.